105 related articles for article (PubMed ID: 15629627)
1. Establishing a prognostic score for primary CNS lymphomas.
Ferreri AJ; Reni M
Int J Radiat Oncol Biol Phys; 2005 Jan; 61(1):303-4; author reply 304-5. PubMed ID: 15629627
[No Abstract] [Full Text] [Related]
2. Cerebrospinal fluid interleukin-10 levels in primary central nervous system lymphoma: a possible marker of response to treatment?
Salmaggi A; Eoli M; Corsini E; Gelati M; Frigerio S; Silvani A; Boiardi A
Ann Neurol; 2000 Jan; 47(1):137-8. PubMed ID: 10632117
[No Abstract] [Full Text] [Related]
3. [Validity of the International Prognostic Index in non-Hodgkin's lymphomas of varying grades of malignancy].
Bettini R; Caronni F; Maino C; Marzetta K; Sala D; Saccà V; Gorini M
Recenti Prog Med; 2003 Nov; 94(11):494-500. PubMed ID: 14679917
[TBL] [Abstract][Full Text] [Related]
4. Retrospective study of prognostic factors in non-Hodgkin lymphoma secondarily involving the central nervous system.
Jahnke K; Thiel E; Martus P; Schwartz S; Korfel A
Ann Hematol; 2006 Jan; 85(1):45-50. PubMed ID: 16132909
[TBL] [Abstract][Full Text] [Related]
5. Central nervous system-directed preventative therapy in adults with lymphoma.
McMillan A
Br J Haematol; 2005 Oct; 131(1):13-21. PubMed ID: 16173958
[TBL] [Abstract][Full Text] [Related]
6. CXCL13 and CXCL12 in central nervous system lymphoma patients.
Fischer L; Korfel A; Pfeiffer S; Kiewe P; Volk HD; Cakiroglu H; Widmann T; Thiel E
Clin Cancer Res; 2009 Oct; 15(19):5968-73. PubMed ID: 19773382
[TBL] [Abstract][Full Text] [Related]
7. [Evaluation of selected clinical prognostic factors in patients with non-granulomatous lymphomas].
Rolski J
Pol Merkur Lekarski; 1997 May; 2(11):324-6. PubMed ID: 9377682
[TBL] [Abstract][Full Text] [Related]
8. [Prognostic factors in non-Hodgkin's lymphomas].
Mayáns J; Sanz G; Monzó E; Sancho-Tello R; Carrera MD; Figueres J; Sanz MA
Rev Clin Esp; 1987 May; 180(8):420-5. PubMed ID: 3616025
[No Abstract] [Full Text] [Related]
9. [Large-cell lymphomas: the International Prognostic Index].
López Guillermo A; Montserrat E
Sangre (Barc); 1992 Oct; 37(5):329-30. PubMed ID: 1293770
[No Abstract] [Full Text] [Related]
10. [How and why have the old drugs changed the prognosis of patients with the primary CNS lymphoma?].
Klabusay M
Vnitr Lek; 2010 Aug; 56(8):785-6. PubMed ID: 20845608
[No Abstract] [Full Text] [Related]
11. Comparative clinicopathological study of primary CNS diffuse large B-cell lymphoma and intravascular large B-cell lymphoma.
Imai H; Shimada K; Shimada S; Abe M; Okamoto M; Kitamura K; Kinoshita T; Shiraishi T; Nakamura S
Pathol Int; 2009 Jul; 59(7):431-7. PubMed ID: 19563405
[TBL] [Abstract][Full Text] [Related]
12. [Tumor markers in malignant lymphoma].
Kato H; Ogura M
Gan To Kagaku Ryoho; 2005 Jun; 32(6):883-92. PubMed ID: 15984537
[TBL] [Abstract][Full Text] [Related]
13. MATILDE regimen followed by radiotherapy is an active strategy against primary CNS lymphomas.
Ferreri AJ; Dell'Oro S; Foppoli M; Bernardi M; Brandes AA; Tosoni A; Montanari M; Balzarotti M; Spina M; Ilariucci F; Zaja F; Stelitano C; Bobbio F; Corazzelli G; Baldini L; Ponzoni M; Picozzi P; Caligaris Cappio F; Reni M
Neurology; 2006 May; 66(9):1435-8. PubMed ID: 16682682
[TBL] [Abstract][Full Text] [Related]
14. Endothelial hyperplasia and endothelial galectin-3 expression are prognostic factors in primary central nervous system lymphomas.
D'Haene N; Catteau X; Maris C; Martin B; Salmon I; Decaestecker C
Br J Haematol; 2008 Feb; 140(4):402-10. PubMed ID: 18081894
[TBL] [Abstract][Full Text] [Related]
15. Cost determinants in aggressive non-Hodgkin's lymphoma.
van Agthoven M; Sonneveld P; Verdonck LF; Uyl-de Groot CA
Haematologica; 2005 May; 90(5):661-71. PubMed ID: 15921381
[TBL] [Abstract][Full Text] [Related]
16. Low serum albumin levels and liver metastasis are powerful prognostic markers for survival in patients with carcinomas of unknown primary site.
Seve P; Ray-Coquard I; Trillet-Lenoir V; Sawyer M; Hanson J; Broussolle C; Negrier S; Dumontet C; Mackey JR
Cancer; 2006 Dec; 107(11):2698-705. PubMed ID: 17063500
[TBL] [Abstract][Full Text] [Related]
17. Comparison of circulating tumor DNA between body fluids in patients with primary central nervous system lymphoma.
Watanabe J; Natsumeda M; Kanemaru Y; Okada M; Oishi M; Kakita A; Fujii Y
Leuk Lymphoma; 2019 Dec; 60(14):3587-3589. PubMed ID: 31305194
[No Abstract] [Full Text] [Related]
18. Serum-soluble tumor necrosis factor receptor 2 (sTNF-R2) level determines clinical outcome in patients with aggressive non-Hodgkin's lymphoma.
Goto N; Tsurumi H; Takemura M; Hara T; Sawada M; Kasahara S; Kanemura N; Yamada T; Shimizu M; Takahashi T; Tomita E; Seishima M; Takami T; Moriwaki H
Eur J Haematol; 2006 Sep; 77(3):217-25. PubMed ID: 16856931
[TBL] [Abstract][Full Text] [Related]
19. Role and prognostic significance of the Ki-67 index in non-Hodgkin's lymphoma.
Broyde A; Boycov O; Strenov Y; Okon E; Shpilberg O; Bairey O
Am J Hematol; 2009 Jun; 84(6):338-43. PubMed ID: 19384938
[TBL] [Abstract][Full Text] [Related]
20. Treatment results of chemoradiation therapy for localized aggressive lymphomas: A retrospective 20-year study.
Yamashita H; Izutsu K; Nakamura N; Shiraishi K; Chiba S; Kurokawa M; Tago M; Igaki H; Ohtomo K; Nakagawa K
Ann Hematol; 2006 Aug; 85(8):523-9. PubMed ID: 16691398
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
